Hepatorenal syndrome

Digestive Diseases

Volumn 23, Issue 1, 2005, Pages 47-55

  Guevara, Mónica ^a,b   Ginès, Pere ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b HOSPITAL CLÍNIC   (Spain)

Author keywords

Ascites; Cirrhosis; Hepatorenal syndrome; TIPS; Vasoconstrictors

Indexed keywords

ACETYLCYSTEINE; ALBUMIN; ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; CATECHOLAMINE; CEFOTAXIME; DOPAMINE; MIDODRINE; NORADRENALIN; OCTREOTIDE; ORNIPRESSIN; PENTOXIFYLLINE; PROSTAGLANDIN; TERLIPRESSIN; VASOCONSTRICTOR AGENT; VASOPRESSIN DERIVATIVE;

ARTERY BLOOD FLOW; BRAIN; CARDIOVASCULAR PERFORMANCE; CLINICAL FEATURE; DETERIORATION; DIAGNOSIS; DISEASE COURSE; HEART; HEART MUSCLE; HEART OUTPUT; HEMODIALYSIS; HEPATORENAL SYNDROME; HUMAN; ISCHEMIA; KIDNEY CIRCULATION; KIDNEY FAILURE; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; LONG TERM CARE; PATHOGENESIS; PORTAL HYPERTENSION; PORTOSYSTEMIC ANASTOMOSIS; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SPLANCHNIC BLOOD FLOW; SURVIVAL RATE; TREATMENT PLANNING; VASOCONSTRICTION; VASODILATATION; VENOUS RETURN;

ALBUMINS; CARDIAC OUTPUT; HEPATORENAL SYNDROME; HUMANS; INFUSIONS, INTRAVENOUS; LIVER; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; PROGNOSIS; REGIONAL BLOOD FLOW; VASOCONSTRICTOR AGENTS;

EID: 20444491155     PISSN: 02572753     EISSN: None     Source Type: Journal    
DOI: 10.1159/000084725     Document Type: Review

References (42)

1. Gines P, Rodes J: Clinical disorders of renal function in cirrhosis with ascites; in Arroyo V, Gines P, Rodes J, Schrier RW (eds): Ascites and renal dysfunction in liver disease, pathogenesis, diagnosis and treatment. Malden, Blackwell Science, 1999, pp 36-62.
2. Hecker R, Sherlock S: Electrolyte and circulatory changes in terminal liver failure. Lancet 1956;ii:1121-1125.
3. Gines P, Guevara M, Arroyo V, Rodes J: Hepatorenal syndrome. Lancet 2003;362:1819-1827.
4. Koppel MH, Coburn JW, Mims MM, Goldstein H, Boyle JD, Rubini ME: Transplantation of cadaveric kidneys from patients with hepatorenal syndrome. Evidence for the functional nature of renal failure in advanced liver disease. N Engl J Med 1969;280:1367-1371.
5. Koppel MH, Coburn JW, Mims MM, Goldstein H, Boyle JD, Rubini ME: Transplantation of cadaveric kidneys from patients with hepatorenal syndrome. Evidence for the functional nature of renal failure in advanced liver disease. N Engl J Med 1969;280:1367-1371.
6. Arroyo V, Gines P, Gerbes AL, Dudley FJ, Gentilini P, Laffi G, et al: Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. International Ascites Club. Hepatology 1996;23:164-176.
7. Akriviadis E, Botla R, Briggs W, Han S, Reynolds T, Shakil O: Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: A double-blind, placebo-controlled trial. Gastroenterology 2000;119:1637-1648.
8. Ellis AJ, O'Grady JG: Clinical disorders or renal function in acute liver failure; in Arroyo V, Gines P, Rodes J, Schrier RW (eds): Ascites and renal dysfunction in liver disease. Malden, Blackwell Science, 1999, pp 63-78.
9. Shear L, Kleinerman J, Gabuzda GJ: Renal failure in patients with cirrhosis of the liver. I. Clinical and pathologic characteristics. Am J Med 1965;39:184-198.
10. Rimola A, Gavaler JS, Schade RR, el Lankany S, Starzl TE, Van Thiel DH: Effects of renal impairment on liver transplantation. Gastroenterology 1987;93:148-156.
11. Papper S, Saxon L: The diuretic response to administered water in patients with liver disease. II. Laennec's cirrhosis of the liver. Arch Intern Med 1959;103:750-757.
12. Iwatsuki S, Popovtzer MM, Corman JL, Ishikawa M, Putnam CW, Katz FH, et al: Recovery from 'hepatorenal syndrome' after orthotopic liver transplantation. N Engl J Med 1973; 289:1155-1159.
13. Gonwa TA, Morris CA, Goldstein RM, Husberg BS, Klintmalm GB: Long-term survival and renal function following liver transplantation in patients with and without hepatorenal syndrome - experience in 300 patients. Transplantation 1991;51:428-430.
14. Schrier RW, Arroyo V, Bernardi M, Epstein M, Henriksen JH, Rodes J: Peripheral arterial vasodilation hypothesis: A proposal for the initiation of renal sodium and water retention in cirrhosis. Hepatology 1988;8:1151-1157.
15. Ruiz-del-Arbol L, Urman J, Fernandez J, Gonzalez M, Navasa M, Monescillo A, et al: Systemic, renal, and hepatic hemodynamic derangement in cirrhotic patients with spontaneous bacterial peritonitis. Hepatology 2003; 38:1210-1218.
16. Guevara M, Gines P, Fernandez-Esparrach G, Sort P, Salmeron JM, Jimenez W, et al: Reversibility of hepatorenal syndrome by prolonged administration of ornipressin and plasma volume expansion. Hepatology 1998;27:35-41.
17. Angeli P, Volpin R, Gerunda G, Craighero R, Roner P, Merenda R, et al: Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide. Hepatology 1999; 29:1690-1697.
18. Gulberg V, Bilzer M, Gerbes AL: Long-term therapy and retreatment of hepatorenal syndrome type 1 with ornipressin and dopamine. Hepatology 1999;30:870-875.
19. Colle I, Durand F, Pessione F, Rassiat E, Bernuau J, Barriere E, et al: Clinical course, predictive factors and prognosis in patients with cirrhosis and type 1 hepatorenal syndrome treated with terlipressin: A retrospective analysis. J Gastroenterol Hepatol 2002;17:882-888.
20. Duvoux C, Zanditenas D, Hezode C, Chauvat A, Monin JL, Roudot-Thoraval F, et al: Effects of noradrenalin and albumin in patients with type I hepatorenal syndrome: A pilot study. Hepatology 2002;36:374-380.
21. Moreau R, Durand F, Poynard T, Duhamel C, Cervoni JP, Ichai P, et al: Terlipressin in patients with cirrhosis and type 1 hepatorenal syndrome: A retrospective multicenter study. Gastroenterology 2002;122:923-930.
22. Ortega R, Gines P, Uriz J, Cardenas A, Calahorra B, De Las HD, et al: Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: Results of a prospective, nonrandomized study. Hepatology 2002; 36:941-948.
23. Wong F, Pantea L, Sniderman K: Midodrine, octreotide, albumin, and TIPS in selected patients with cirrhosis and type 1 hepatorenal syndrome. Hepatology 2004;40:55-64.
24. Mulkay JP, Louis H, Donckier V, Bourgeois N, Adler M, Deviere J, Le Moine O: Long-term terlipressin administration improves renal function in cirrhotic patients with type 1 hepatorenal syndrome: a pilot study. Acta Gastroenterol Belg 2001;64:15-19.
25. Uriz J, Gines P, Cardenas A, Sort P, Jimenez W, Salmeron JM, et al: Terlipressin plus albumin infusion: An effective and safe therapy of hepatorenal syndrome. J Hepatol 2000;33:43-48.
26. Restuccia T, Ortega R, Guevara M, Gines P, Alessandria C, Ozdogan O, et al: Effects of treatment of hepatorenal syndrome before transplantation on posttransplantation outcome. A case-control study. J Hepatol 2004;40: 140-146.
27. Rossle M: The transjugular intrahepatic portosystemic shunt. J Hepatol 1996;25:224-231.
28. Brensing KA: PJST. TIPS in hepatorenal syndrome: in Arroyo V (ed): Treatment of Liver Diseases. Barcelona, Masson, 1999, pp 53-59.
29. Brensing KA, Textor J, Perz J, Schiedermaier P, Raab P, Strunk H, et al: Long term outcome after transjugular intrahepatic portosystemic stent-shunt in non-transplant cirrhotics with hepatorenal syndrome: A phase II study. Gut 2000;47:288-295.
30. Guevara M, Gines P, Bandi JC, Gilabert R, Sort P, Jimenez W, et al: Transjugular intrahepatic portosystemic shunt in hepatorenal syndrome: Effects on renal function and vasoactive systems. Hepatology 1998;28:416-422.
31. Gines A, Escorsell A, Gines P, Salo J, Jimenez W, Inglada L, et al: Incidence, predictive factors, and prognosis of the hepatorenal syndrome in cirrhosis with ascites. Gastroenterology 1993;105:229-236.
32. Kamath PS, Wiesner RH, Malinchoc M, Kremers W, Therneau TM, Kosberg CL, et al: A model to predict survival in patients with end-stage liver disease. Hepatology 2001;33:464-470.
33. Malinchoc M, Kamath PS, Gordon FD, Peine CJ, Rank J, ter Borg PC: A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts. Hepatology 2000;31:864-871.
34. Jeyarajah DR, Gonwa TA, McBride M, Testa G, Abbasoglu O, Husberg BS, et al: Hepatorenal syndrome: Combined liver kidney transplants versus isolated liver transplant. Transplantation 1997;64:1760-1765.
35. Arroyo V, Guevara M, Gines P: Hepatorenal syndrome in cirrhosis: Pathogenesis and treatment. Gastroenterology 2002; 122: 1658-1676.
36. Pomier-Layrargues G, Paquin SC, Hassoun Z, Lafortune M, Tran A: Octreotide in hepatore-nal syndrome: A randomized, double-blind, placebo-controlled, crossover study. Hepatology 2003;38:238-243.
37. Holt S, Goodier D, Marley R, Patch D, Burroughs A, Fernando B, et al: Improvement in renal function in hepatorenal syndrome with N-acetylcysteine. Lancet 1999;353:294-295.
38. Mitzner SR, Klammt S, Peszynski P, Hickstein H, Korten G, Stange J, et al: Improvement of multiple organ functions in hepatorenal syndrome during albumin dialysis with the molecular adsorbent recirculating system. Ther Apher 2001;5:417-422.
39. Moore KP, Wong F, Gines P, Bernardi M, Ochs A, Salerno F, et al: The management of ascites in cirrhosis: Report on the consensus conference of the International Ascites Club. Hepatology 2003;38:258-266.
40. Alessandria C, Venon WD, Marzano A, Barletti C, Fadda M, Rizzetto M: Renal failure in cirrhotic patients: Role of terlipressin in clinical approach to hepatorenal syndrome type 2. Eur J Gastroenterol Hepatol 2002;14:1363-1368.
41. Gines P, Uriz J, Calahorra B, Garcia-Tsao G, Kamath PS, Del Arbol LR, et al: Transjugular intrahepatic portosystemic shunting versus paracentesis plus albumin for refractory ascites in cirrhosis. Gastroenterology 2002;123:1839-1847.
42. Sort P, Navasa M, Arroyo V, Aldeguer X, Planas R, Ruiz-del-Arbol L, et al: Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med 1999;341: 403-409.